Given the bioanalytical complexities involved in ADC development—including various immunogenic impacts of all ADC components and the need for rigorous analysis of total ADC, monoclonal antibody (mAb) and free toxin—you need a bioanalytical services partner with extensive experience in bringing these treatments to market. At Labcorp, we are proud to be a highly experienced bioanalytical ADC development partner, currently supporting one-third of all ADCs in mid- to late-stage clinical trials.

• Download